Navigation Links
Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Date:12/18/2007

SAN DIEGO, Dec. 18 /PRNewswire/ -- Ambrx Inc. today announced that it has entered into a global, strategic collaboration with Merck & Co. Inc. to develop a novel therapeutic protein with biological properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders such as obesity.

The collaboration utilizes Ambrx's proprietary protein technology, ReCODE(TM), to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.

"We are pleased to enter into this agreement with Merck, a world leader in the metabolic diseases field with a proven track record in the rapid development and launch of diabetes medicines," said Stephen W. Kaldor, Ph.D., Ambrx's president and chief executive officer. "We are excited about the potential of our initial FGF-21 protein drug candidates, as they promise unique pharmacological efficacy in the treatment of diabetes, a disease of large and rapidly increasing prevalence."

"Molecules capable of mimicking the biological properties of the natural protein FGF-21 represent promising candidates for the treatment of metabolic disorders such as type 2 diabetes and obesity," said Luciano Rossetti, M.D., senior vice president and franchise head, Diabetes/Obesity and Cardiovascular Franchises at Merck. "Ambrx has developed several novel preclinical protein therapeutic candidates designed to provide enhanced therapeutic properties that may complement our portfolio of products for people with metabolic disorders."

The transaction includes an initial upfront payment in addition to committed R&D payments. Ambrx will also be eligible to receive future milestone payments associated with research, development and commercialization of a drug candidate resulting from the collaboration along with royalties on net sales. Ambrx also has the right to exercise an "end of Phase II" profit sharing option. Additional terms of the agreement were not disclosed. It is expected that this collaboration, in conjunction with three others announced this year, will preclude the necessity for Ambrx to raise additional equity capital for a number of years.

About Ambrx

Ambrx Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class and best-in-class BioSuperior(TM), protein-based drugs. Using its technology, the company can overcome the performance limitations of high-value commercial proteins by improving their efficacy, safety and ease of use. Ambrx's core ReCODE(TM) technology enables the precise, site-specific substitution of a novel amino acid within a protein. This allows the conjugation of proteins with additional molecules that can serve to modulate their pharmacokinetic profile or biological function. Ambrx's ReCODE(TM) technology is applicable to multiple protein products across numerous therapeutic areas. Ambrx has successfully and rapidly applied its innovative technology platform to advance into the clinic with ARX201, its first proprietary molecule, and is building a broad pipeline of additional product opportunities. For additional information, call 858.875.2400 or visit http://www.ambrx.com.


'/>"/>
SOURCE Ambrx Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
10. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2018)... ... November 09, 2018 , ... OnlineMasters.com, an industry-leading ... Psychology Programs for 2019. They have identified the top programs in the nation ... and graduate outcomes. , Leveraging an exclusive data set comprised of interviews and ...
(Date:11/9/2018)... ... November 09, 2018 , ... One in seven Americans ... that makes Thanksgiving food drives urgently important. Yet, despite good intentions, people often ... donations. Colorado-based nonprofit Heaven On Earth NOW has launched a “Think Before You ...
(Date:11/9/2018)... ... ... Triple W, an innovator of connected health devices, today announced that it has ... the first health tech wearable device for incontinence that monitors how full your bladder ... was made during CES Unveiled New York, an invite-only tech event bringing together top ...
Breaking Medicine Technology:
(Date:11/9/2018)... ... November 09, 2018 , ... ... has awarded microbiome research support in study design, planning, sample collection, and analysis ... Sospedra, PhD, to study the effects of a nutritional intervention on the sports ...
(Date:11/9/2018)... ... November 08, 2018 , ... ... HPH Hospice and LifePath Hospice ) announced today Dean H. ... December 3, 2018. Forman will report directly to President and Chief Executive Officer ...
(Date:11/8/2018)... ... November 08, 2018 , ... How ... different media sources could impact how they view advertising and earned media in ... Connections, Inc. will release results of the tenth annual study of the media ...
(Date:11/8/2018)... (PRWEB) , ... November 08, 2018 , ... Dutch Bros ... of Breast Cancer Awareness Month. For each custom “Be Aware” mug sold in October, ... “We are so proud of the support our customers showed for these amazing organizations,” ...
(Date:11/8/2018)... ... November 08, 2018 , ... Porchlight VNA/Home Care ... enhance disease management for high risk patients. , Porchlight VNA/Home Care plans to ... for hospital readmissions and emergency department visits, primarily patients with CHF and COPD. ...
Breaking Medicine News(10 mins):